Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-92P is a member of the large set of U6 small nuclear RNA pseudogenes, which are genomic elements resembling the functional U6 snRNA gene but lack the ability to encode a functional RNA molecule[3]. U6 snRNA itself is a highly conserved non-coding RNA, essential for the splicing of pre-mRNA as a part of the spliceosome complex, and it is found in many functional gene copies as well as numerous pseudogenes in the human genome[3][1]. Pseudogenes like RNU6-92P are nonfunctional byproducts of genome evolution and do not produce active RNA or protein products; thus, they do not have therapeutic targeting potential or roles in disease as functional entities[3]. Summary of Key Points: - RNU6-92P is a pseudogene and not a functional gene or therapeutic target[3]. - It is derived from the U6 small nuclear RNA gene family, which is essential for RNA splicing, but pseudogenes do not play an active biological role[3][4]. - There are no known drugs, biomarkers, safety, or disease associations specific to this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 92, pseudogene (RNU6-92P).